@article{ATM6097,
author = {Christopher R. Pierson},
title = {Gene therapy in myotubular myopathy: promising progress and future directions},
journal = {Annals of Translational Medicine},
volume = {3},
number = {5},
year = {2015},
keywords = {},
abstract = {X-linked myotubular myopathy (MTM; OMIM 310400) is a severe congenital myopathy that is classified as one of the centronuclear myopathies (1). MTM is estimated to affect 1/50,000 live born males and is due to loss of function mutations in MTM1, which encodes myotubularin, a ubiquitously expressed lipid phosphatase (2,3). The function of myotubularin is still not entirely clear, but a picture is starting to emerge in which myotubularin is a critical maintenance protein of the myofiber sarcotubular system and has a role in excitation-contraction coupling (4-7).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/6097}
}